ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, today announced that Xellera Therapeutics has been awarded a US$150,000 G-Rex® Grant to support the establishment of a highly efficient cGMP G-Rex® centric NK cell...
News
Corporate News and Press Releases
Cell Therapies and Xellera Therapeutics Enter into a Strategic Partnership to Fast-Track Access to Cell and Gene Therapies across APAC
Cell Therapies and Xellera Therapeutics Forge Partnership: Signing a Memorandum of Understanding (MoU) to accelerate the development and accessibility of life-changing cell and gene therapies across the Asia-Pacific region. This partnership will offer new...
Xellera Therapeutics Launched Hong Kong’s First Current Good Manufacturing Practice (cGMP) Facility For Cell & Gene Therapy Products
Xellera hosted its First Press Conference in February 2021.Prof. Ronald Li, Prof. Godfrey Chan, Prof. Paul Tam Spoke on cGMP Facilities and Cell & Gene Therapies and Launch Hong Kong’s First Current Good Manufacturing Practice (cGMP)... Xellera Therapeutics...
Technology News
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends Novartis’ CAR T-cell therapy for follicular lymphoma
The EMA has recommended granting European Commission (EC) approval to Novartis’ CAR T-cell therapy, Kymriah® (tisagenlecleucel), to treat adult relapsed or refractory (r/r) follicular lymphoma (FL) patients. In April 2020, the US Food and Drug Administration granted...
Decade-Long Remission After CAR T-cell therapy reported
Researcher reported in Nature in March 2022, that the first two patients who received an infusion of autologous CAR T-cells in 2010 when they were no longer responsive to chemotherapy, remain in remission. Their CAR T-cell population are still proliferating in their...